(Received for publication, August 23, 1995; and in revised form, January 3, 1996)
From the
Cryptophycin is a potent antitumor agent that depletes microtubules in intact cells, including cells with the multidrug resistance phenotype. To determine the mechanism of action of cryptophycin, its effects on tubulin function in vitro were analyzed. Cryptophycin reduced the in vitro polymerization of bovine brain microtubules by 50% at a drug:tubulin ratio of 0.1. Cryptophycin did not alter the critical concentration of tubulin required for polymerization, but instead caused substoichiometric reductions in the amount of tubulin that was competent for assembly. Consistent with its persistent effects on intact cells, cryptophycin-treated microtubule protein remained polymerization-defective even after cryptophycin was reduced to sub-inhibitory concentrations. The effects of cryptophycin were not due to denaturation of tubulin and were associated with the accumulation of rings of microtubule protein.
The site of cryptophycin interaction
with tubulin was examined using functional and competitive binding
assays. Cryptophycin blocked the formation of vinblastine-tubulin
paracrystals in intact cells and suppressed vinblastine-induced tubulin
aggregation in vitro. Cryptophycin inhibited the binding of
[H]vinblastine and the hydrolysis of
[
-
P]GTP by isolated tubulin, but did not
block the binding of colchicine. These results indicate that
cryptophycin disrupts the Vinca alkaloid site of tubulin;
however, the molecular details of this interaction are distinct from
those of other antimitotic drugs.
Microtubules are extraordinarily dynamic assemblies, which are involved in many cellular activities including maintenance of cell structure and regulation of cell motility, membrane transport processes and cell proliferation (reviewed in (1) ). The process of continuous addition and loss of tubulin dimers from microtubule ends, termed dynamic instability(2) , allows rapid remodeling of these structures, but also makes them susceptible to chemical agents that disrupt microtubule structure and function. Inhibition of microtubule dynamics in the mitotic spindle is thought to be the basis for the anticancer activities of drugs that promote the depolymerization of microtubules, e.g. Vinca alkaloids, or that stabilize microtubules, e.g. taxanes(3, 4, 5, 6, 7) . These compounds are widely used clinically; however, the ability of tumor cells to develop resistance to these, and most other, natural product anticancer drugs often limits their ultimate efficacy (reviewed in (8, 9, 10) ).
We have recently described the ability of a cyanobacterial cytotoxic macrolide, termed cryptophycin, to induce the depletion of microtubules in intact cells(11) . Importantly, cryptophycin is able to circumvent a common form of multiple drug resistance, i.e. P-glycoprotein-mediated efflux of natural product anticancer drugs. This confers a significant theoretical advantage to this compound over currently utilized antimitotic drugs in that tumors should be less able to develop resistance to cryptophycin. Cryptophycin has demonstrated excellent in vivo activity against several types of tumor xenografts, including those of cells that are poorly inhibited by Vinca alkaloids(12) . Because of the potential usefulness of cryptophycin as an anticancer drug, we have now examined the molecular mechanism of its antimicrotubule actions. These studies have revealed that cryptophycin interacts with the Vinca alkaloid binding domain of tubulin; however, a number of unique molecular details of cryptophycin binding have been identified.
Figure 1: Structure of cryptophycin.
1) To examine the effects of drugs on microtubule
depolymerization, MTP was polymerized in the absence or presence of 10
µM paclitaxel for 30 min under the conditions described
above. Cryptophycin or vinblastine was then added, and the A was monitored for approximately 30 min.
2) To examine the effects of drugs on microtubule morphology, MTP samples were incubated with drug under polymerizing conditions for 30 min. The samples were then fixed with 0.2% glutaraldehyde, absorbed onto carbon-coated grids, and stained with 0.5% uranyl acetate for electron microscopy.
3) To test the effects of cryptophycin on the critical concentration of tubulin, the amount of MTP was varied from 0.25 to 5 mg/ml (2-40 µM tubulin) and cryptophycin concentrations were varied from 0 to 10 µM. Polymerization was initiated and monitored as indicated above.
4) To test the
reversibility of the inhibitory effect of cryptophycin, MTP was
incubated with 5 µM cryptophycin for 30 min at room
temperature in MTP polymerizing buffer (without GTP). The samples were
then diluted 10-fold with cold MTP polymerizing buffer and concentrated
10-80-fold by ultrafiltration using Centricon-10 centrifugal
concentrators (Amicon, Inc., Beverly, MA), which contain M 10,000 cut-off filters. After measurement of the
volume of the concentrate, the samples were diluted to their original
volume (0.25 ml) so that the MTP was restored to its original
concentration and cryptophycin was reduced to
0.5 µM.
A 0.2-ml aliquot was then combined with 0.5 mM GTP and warmed
to 37 °C, and polymerization was monitored as indicated above. The
remainder of the sample was combined with 9 volumes of cold EtOH, and
precipitated protein was pelleted by centrifugation at 15,000
g for 10 min. The supernatant was serially diluted and tested
for cytotoxicity toward MCF-7 cells as described previously (11) . The actual amount of cryptophycin in each centrifuged
sample was determined by comparison with the cytotoxicities of
cryptophycin standards.
1) In the colchicine binding
assay(18) , triplicate samples of bovine brain MTP (10
µM tubulin) were incubated with cryptophycin,
podophyllotoxin or vinblastine in 0.1 M MES, pH 6.6,
containing 1 mM MgCl, 1 mM GTP, 100
mM glucose 1-phosphate(19) , for 5 min before the
addition of 10 µM colchicine. After 30 min, the
fluorescence of the MTP mixture were determined using an excitation
wavelength of 357 nm and an emission wavelength of 435 nm. Increased
fluorescence of colchicine is observed upon its binding to tubulin (18) . Samples without colchicine or without MTP were utilized
as blanks.
2) In the [H]vinblastine binding
assay(20) , triplicate samples of MTP (2 µM tubulin) were incubated in 0.1 M MES, pH 6.9, containing
0.5 mM MgCl
, 2% dimethyl sulfoxide, and 5
µM [
H]vinblastine (0.1 µCi) with
several concentrations of test drugs for 30 min at 21 °C. The
samples (0.15 ml) were then applied to 0.5-ml columns of Sephadex G-50
equilibrated with incubation buffer without vinblastine and centrifuged
at 100
g for 2 min. Additional buffer (0.3 ml) was
then added to each column, and the samples were centrifuged again. An
aliquot of the filtrate (0.25 ml) containing bound
[
H]vinblastine was analyzed by liquid
scintillation counting. Blank samples did not contain MTP, and their
counts were subtracted from test samples.
3) In the
[H]GTP binding assay, triplicate samples of MTP
(20 µM tubulin) were incubated in 0.1 M MES, pH
6.9, containing 0.5 mM MgCl
, 2% dimethyl
sulfoxide, and 0.1 mM [
H]GTP (0.2
µCi) with several concentrations of test drugs for 30 min at 21
°C. Bound [
H]GTP was determined by
centrifugal filtration on Sephadex G-50 as described above. Blank
samples did not contain MTP, and their counts were subtracted from test
samples.
4) In the GTPase assay(21) , triplicate samples of
20 µM purified tubulin were incubated in 1 M glutamate, pH 6.9, containing 0.5 mM MgCl, 2%
dimethyl sulfoxide, and 0.1 mM [
-
P]GTP (0.1 µCi) (22) with several concentrations of test drugs for 5 min at 37
°C. Reactions were terminated by the addition of 1 ml of 300 mM perchloric acid containing 10 mg of activated charcoal (23) . Samples were then incubated at room temperature for 5
min to allow adsorption of the nucleotide to the charcoal, followed by
centrifugation at 3,000
g for 5 min. An aliquot (0.25
ml) of the supernatant was removed and analyzed by liquid scintillation
counting to determine the amount of released
PO
. Blank samples did not contain MTP, or were
stopped immediately after the addition of
[
-
P]GTP, and their counts were subtracted
from test samples.
5) To quantify the rates of tubulin
denaturation(24) , purified tubulin (5 µM) was
incubated at 37 °C in 100 mM MES, pH 6.4, containing 0.1
mM EDTA, 1 mM EGTA, 1 mM GTP, 0.5 mM MgCl, and 1 mM
-mercaptoethanol in the
absence or presence of cryptophycin. At 30-min intervals, samples were
combined with 25 µM bisANS and the fluorescence was
determined using an excitation wavelength of 385 nm and an emission
wavelength of 490 nm (24) . Samples without bisANS or without
tubulin were utilized as blanks.
Additionally, the K/SDS precipitation assay
was used to test the effects of drugs on topoisomerases in intact
cells(27) . Briefly, SKOV3 cells were grown for 24 h in the
presence of [
H]thymidine (1 µCi/ml) in
24-well tissue culture plates. At that time, the medium was replaced
with unlabeled medium containing 10% fetal bovine serum and cells were
exposed to multiple doses of test drugs for 45 min. The cells were then
lysed with 1.25% SDS, and protein-complexed DNA was precipitated by the
addition of 325 mM KCl. Pellets were washed twice, and the
amount of precipitated
H was determined by liquid
scintillation counting.
Figure 2:
Effects of antimitotic drugs on MTP
polymerization. Microtubule protein (20 µM tubulin) was
incubated with EtOH (), 5 µM colchicine (
), 5
µM vinblastine (
), or 5 µM cryptophycin (
) for 15 min before the addition of GTP and
warming to 37 °C as described under ``Materials and
Methods.'' Polymerization was monitored as light scattering (A
) at 20-s
intervals.
Substoichiometric doses of cryptophycin (with respect to tubulin) suppressed microtubule assembly (Fig. 3A), such that polymerization was decreased by approximately 50% by a cryptophycin:tubulin ratio of 0.1. Cryptophycin concentrations of 0.5 µM and below did not affect microtubule assembly. In contrast with vinblastine(4) , high doses of cryptophycin (up to at least 40 µM) did not promote the formation of aberrant tubulin aggregations that result in increased light scattering (data not shown). Cryptophycin also suppressed the ability of purified tubulin to assemble into microtubules (Fig. 3B), indicating that the molecular target of the compound is tubulin rather than a MAP. To examine the polymerization of tubulin in the absence of MAPs, it is necessary to utilize reaction conditions which strongly promote microtubule assembly, i.e. 1 M glutamate, pH 6.6, containing 4% dimethyl sulfoxide(4) . The reduced effect of cryptophycin on purified tubulin most likely reflects the difficulty in blocking assembly under these conditions.
Figure 3:
Dose-response curves for inhibition of
polymerization by cryptophycin. A, microtubule protein (20
µM tubulin) was incubated with 0 (), 2(
), 5
(
), or 10 (
) µM cryptophycin for 15 min
before polymerization was initiated as described under ``Materials
and Methods.'' B, purified tubulin (20 µM tubulin) was incubated with 0 (
), 0.5 (
), or 5
(
) µM cryptophycin for 15 min before
polymerization was initiated as described under ``Materials and
Methods.''
Experiments in which the concentrations of both tubulin and cryptophycin were varied indicated that the compound altered the percentage of tubulin which was competent for assembly, but did not alter the critical concentration of tubulin required for assembly (Fig. 4). These effects of cryptophycin are clearly substoichiometric with respect to tubulin, e.g. increasing tubulin from 10 to 40 µM allowed only a small increase in assembly in the presence of 5 µM cryptophycin. Electron microscopy revealed that MTP incubated with cryptophycin accumulated as rings (Fig. 5). The scattered aggregates of protein do not have structural similarity with spirals formed in the presence of vinblastine ( (28) and data not shown).
Figure 4:
Effect of cryptophycin on the critical
concentration of tubulin. Dilutions of MTP containing the indicated
concentrations of tubulin were incubated with 0 (), 2 (
),
5 (
), or 10 (
) µM cryptophycin for 15 min
before polymerization was initiated as described under ``Materials
and Methods.'' In all cases, polymerization plateaued by 30 min,
and this maximum increase in A
is indicated.
These results are from one of two virtually identical
experiments.
Figure 5:
Electron microscopy of
cryptophycin-treated MTP. Microtubule protein was incubated with 5
µM cryptophycin before assembly was initiated as indicated
in Fig. 2. After 30 min, samples were fixed with glutaraldehyde
and examined by transmission electron microscopy as indicated under
``Materials and Methods.'' A typical field is shown.
Magnification, 150,000.
Pretreatment of intact cells with paclitaxel prevents microtubule depletion upon exposure to cryptophycin or vinblastine(11) . To test the effects of paclitaxel in vitro, microtubules were assembled in the absence or presence of 10 µM paclitaxel and then exposed to cryptophycin or vinblastine. As demonstrated in Fig. 6, addition of cryptophycin to microtubules assembled in the absence of paclitaxel led to rapid, partial disassembly, manifested as a decrease in turbidity. In contrast, vinblastine was ineffective in reducing the state of microtubule assembly. Paclitaxel enhanced microtubule assembly, in agreement with previous studies(29) , and markedly reduced the ability of cryptophycin to induce disassembly.
Figure 6:
Effects of vinblastine and cryptophycin on
MTP depolymerization. Microtubule protein (20 µM tubulin)
was incubated with EtOH (open symbols) or 10 µM paclitaxel (closed symbols) for 15 min before
polymerization was initiated (time = 0). After 20 min, 10
µM vinblastine (,
) or 10 µM cryptophycin (
,
) was added and light scattering was
monitored for an additional 20 min.
Treatment of cells with cryptophycin results in irreversible depletion of microtubules(11) . To test the reversibility of the in vitro effects of the compound, MTP was treated with 5 µM cryptophycin, concentrated 10- or 30-fold by ultrafiltration, and then diluted to the original volume. Residual concentrations of cryptophycin in the MTP sample were quantified by a bioassay for cytotoxicity and were found to amount to 0.16 and 0.085 µM. Results from six samples indicated that actual residual cryptophycin concentrations averaged 48 ± 8% of the theoretical residual concentration, i.e. calculated on the basis of the dilution factor, suggesting limited binding to the concentrator. The polymerization ability of MTP incubated in the absence of cryptophycin was reduced by approximately 50% by these manipulations. However, MTP that had been incubated with cryptophycin was unable to assemble (Fig. 7), even when residual levels of cryptophycin were reduced to 0.085 µM. This concentration of cryptophycin has no effect on MTP assembly, indicating that treatment with cryptophycin caused persistent inhibition of assembly.
Figure 7:
Lack of reversibility of effects of
cryptophycin. Microtubule protein was incubated with 0 () or 5
(
,
) µM cryptophycin for 15 min as described
for Fig. 2. The samples were then diluted 10-fold, concentrated
by ultrafiltration either 10-fold (
) or 30-fold (
) using
Centricon-10 centrifugal concentrators and diluted to the original
volume as described under ``Materials and Methods.'' The
residual concentrations of cryptophycin were measured by a bioassay,
and were found to be 0 (
), 0.05 (
), and 0.5 (
)
µM. Results from one of four experiments (in which
concentration factors ranged from 10- to 80-fold) are
shown.
Incubation of tubulin at 37 °C results in time-dependent denaturation that can be monitored as increased binding of bisANS to hydrophobic sites(24) . Cryptophycin (5 µM or greater) completely blocked the spontaneous increase in the ability of tubulin to bind bisANS (data not shown). This stabilization of tubulin supports the hypothesis that cryptophycin binds directly to tubulin and indicates that the persistence of the inhibitory effect of cryptophycin of polymerization is not due to nonspecific denaturation of tubulin.
Figure 8:
Effects of antimitotic drugs on
vinblastine and colchicine binding to tubulin. Panel A,
microtubule protein was incubated with the indicated concentrations of
colchicine (), vinblastine (
), podophyllotoxin (
),
rhizoxin (
), or cryptophycin (
) before the binding of
[
H]vinblastine was determined as indicated under
``Materials and Methods.'' Values represent the mean ±
S.E. for three experiments with each ligand. Panel B,
microtubule protein was incubated with the indicated concentrations of
cryptophycin (
), vinblastine (
), or podophyllotoxin
(
) before the addition of 10 µM colchicine. After
30 min the fluorescence at 435 nm was determined. Additional samples
were incubated with the indicated concentrations of cryptophycin
(
) without the addition of colchicine. The fluorescence value of
MTP in the absence of drug was subtracted from each sample. Data from
one of three similar experiments are shown.
Colchicine binding to tubulin can be monitored by
an increase in its fluorescence at 435 nm(18) . Pretreatment of
MTP with podophyllotoxin strongly reduced colchicine binding, whereas
neither vinblastine nor cryptophycin altered the increased fluorescence
of colchicine upon its interaction with tubulin (Fig. 8B). Cryptophycin alone did not alter
fluorescence at 435 nm (open triangles), or the absorption
spectrum of the MTP (data not shown). In a complimentary assay, the
effects of these agents on the photolabeling of tubulin by
[H]colchicine (26) were determined.
Covalent incorporation of [
H]colchicine into
tubulin dimers upon exposure to UV light was inhibited by pretreatment
of the MTP with 20 µM of either podophyllotoxin or
unlabeled colchicine (to 57 and 51% of the control value,
respectively). In contrast, pretreatment with 20 µM vinblastine or rhizoxin did not have reduce the photolabeling of
tubulin by [
H]colchicine, and cryptophycin
reduced labeling to only 79% of the control value.
Cryptophycin and
vinblastine caused virtually parallel dose-dependent inhibitions of the
hydrolysis of [-
P]GTP by purified tubulin,
each reaching 10% of the control activity at 10 µM (data
not shown). Neither cryptophycin nor vinblastine altered
[
H]GTP binding to MTP (data not shown).
To
verify the ability of cryptophycin to modulate the Vinca binding domain of tubulin, its effects on the formation of
vinblastine-tubulin paracrystals in intact cells were examined.
Treatment of ovarian carcinoma (SKOV3) cells with 5 µM vinblastine resulted in the depletion of microtubules and the
formation of large paracrystals of vinblastine-tubulin (Fig. 9).
Treatment of cells with 5 µM colchicine, 5 µM rhizoxin, or 25 nM cryptophycin depleted microtubules,
resulting in diffuse cytoplasmic staining of -tubulin. Addition of
vinblastine to colchicine-treated cells resulted in the formation of
paracrystals; however, no paracrystals were formed in cells pretreated
with either rhizoxin or cryptophycin. Similarly, pretreatment of MTP in vitro with 10 µM cryptophycin blocked the
ability of high doses of vinblastine (up to at least 80
µM) to cause tubulin aggregation (data not shown).
Figure 9:
Effects of antimitotic drugs on
vinblastine-tubulin paracrystal formation. SKOV3 cells were treated
with EtOH (top row), 5 µM colchicine (second
row), 5 µM rhizoxin (third row), or 25
nM cryptophycin (bottom row) for 3 h before the
addition of 0 (left column) or 5 µM vinblastine (right column). Cells were incubated an additional 18 h, and
-tubulin was stained as indicated under ``Materials and
Methods.''
Our initial descriptions of the actions of cryptophycin were limited to cellular studies in which this cyanobacterial natural product demonstrated extremely potent cytotoxicity, which was closely correlated with mitotic arrest, and pronounced, irreversible depletion of cellular microtubules(11) . A major point of interest with this compound is its ability to kill cells that are resistant to other antimitotic drugs, including vinblastine and paclitaxel. Because of this, cryptophycin is an attractive agent for development as an anticancer drug. To further characterize the molecular actions of cryptophycin, we have now examined the effects of this compound on tubulin function in vitro.
Antimitotic compounds commonly
disrupt mitotic spindle function by interfering with microtubule
dynamics(30, 31, 32) , and this effect is
reflected in their abilities to modulate the assembly of microtubules in vitro. As with other microtubule-depleting agents,
cryptophycin strongly suppressed the ability of microtubules to
assemble in vitro, indicating that the target of its action is
contained in these preparations. Cryptophycin inhibited the assembly of
purified tubulin, prevented tubulin denaturation, inhibited
tubulin's ability to bind [H]vinblastine
and to hydrolyze [
-
P]GTP. These results
demonstrate that cryptophycin directly interacts with tubulin. Similar
reduced efficacy for inhibition of the assembly of purified tubulin in
comparison with assembly of microtubules from MTP has been observed
with other antimitotic compounds (19, 33, 34) and most likely reflects the
difficulty in preventing polymerization under conditions that strongly
favor assembly, i.e. high glutamate and dimethyl sulfoxide
concentrations(4) .
Microtubules assembled in the presence of paclitaxel were stable upon treatment with cryptophycin, suggesting that cryptophycin binds to unpolymerized tubulin and prevents the growth of microtubules. Additionally, the effects of paclitaxel on alterations of microtubules in intact cells by cryptophycin (11) are fully mimicked by the MTP preparation, indicating that no other regulatory proteins mediate the actions of cryptophycin.
Interestingly, cryptophycin did not alter the critical concentration for microtubule assembly as has been reported for other tubulin-binding agents(35, 36, 37, 38) . Instead, cryptophycin induced substoichiometric reductions in the maximum extent of assembly. This is consistent with an ``end-poisoning'' model in which addition of tubulin-cryptophycin complexes to the microtubule blocks further elongation(39, 40) . In support of this mechanism, electron microscopy indicated that the modest increase in turbidity of MTP incubated in the presence of cryptophycin is associated with the accumulation of tubulin rings (Fig. 3). These structures have been previously observed under conditions in which the formation of microtubules is prevented by low temperature or lack of GTP(41) , and strikingly contrast with the effects of vinblastine and colchicine which induce the accumulation of spirals (28) and twisted ribbons(42) , respectively.
It may be noted that microtubule depletion in intact
cells can be accomplished by nanomolar doses of cryptophycin, while
inhibition of microtubule polymerization in vitro requires
micromolar levels of the compound. This apparent discrepancy is also
observed with Vinca alkaloids(43) , paclitaxel (32) and colchicine, ()and is due to the high
concentration of tubulin needed to measure microtubule assembly in
vitro, i.e. 20 µM. Consequently, effects
mediated by stoichiometric binding of the agent to tubulin are observed
only at micromolar concentrations. Additionally, other tubulin-binding
drugs have been shown to concentrate >100-fold within cells, greatly
increasing their effective levels at the target site. It is likely that
this consideration also applies to cryptophycin. Recent work has
demonstrated that microtubule dynamicity, i.e. addition and
removal of tubulin dimers from microtubule ends, is considerably more
sensitive to inhibition by antimitotic drugs than are alterations of
total cellular microtubule mass(30, 31, 32) .
In support of a similar mechanism for cryptophycin, dual-labeling
studies have demonstrated that cryptophycin induces mitotic arrest and
apoptosis in cells with intact cytoplasmic microtubules. (
)
Since the time that tubulin was identified as the intracellular binding site of colchicine(44) , a number of natural and synthetic compounds that alter microtubule structure and function have been characterized. Natural products that act as antimitotic agents due to depletion of cellular microtubules have been classified according to their abilities to bind to either the colchicine site or the vinblastine site of tubulin(4) . While neither drug-binding site has been structurally characterized, some similarities among compounds interacting with these sites can be recognized. The classification of new compounds generally relies on study of their effects on the binding of colchicine and vinblastine. To date, compounds (and their analogues) have segregated quite well into these two categories. For example, Vinca alkaloids, rhizoxin(45) , maytansinoids(46) , phomopsins(47) , dolastatins(48) , halichondrins(33) , ustiloxins(49) , and spongistatin (50) interact with the ``vinblastine'' site, while colchicine, podophyllotoxins(51) , steganacin(52) , combrestatins(53) , and curacin A (54) interact with the ``colchicine'' site.
Interaction of cryptophycin with
the Vinca alkaloid binding site of tubulin is indicated by its
ability to inhibit the binding of [H]vinblastine,
as well as its ability to inhibit the formation of drug-tubulin
paracrystals in cells or MTP treated with high doses of vinblastine.
Attempts to use the DEAE-filter assay to measure
[
H]colchicine binding to tubulin (19) resulted in very low binding stoichiometry (<0.1),
clearly indicating that the reaction had not reached equilibrium. This
probably reflects the relatively low k
for
colchicine interaction with tubulin (4, 55) and the
instability of the colchicine binding site of tubulin incubated at 37
°C(4) . Therefore, two independent assays were used to
examine the interaction of cryptophycin with tubulin. These studies
indicated that cryptophycin did not alter photolabeling of tubulin by
[
H]colchicine or alter increases in colchicine
fluorescence upon its binding to tubulin (Fig. 8B).
The properties of previously known natural products which modulate the Vinca alkaloid domain of tubulin have recently been summarized by Luduena et al.(56) and indicate that cryptophycin has molecular effects that are unique. For example, vinblastine, phomopsin A, and dolastatin 10 enhance colchicine binding to tubulin, whereas cryptophycin is without effect. Tubulin decay in vitro is strongly inhibited by cryptophycin, vinblastine, phomopsin A, ustiloxin A, and dolastatin 10, but is increased or not affected by maytansine, rhizoxin, homohalichondrin B, and halichondrin B. Binding of GTP to tubulin is not affected by cryptophycin or vinblastine, but is inhibited by the other natural products. Cryptophycin and vinblastine have markedly different effects on tubulin structure both in vitro and in intact cells. Therefore, cryptophycin binding to tubulin is mechanistically different from previously described compounds and so should be useful in further defining drug binding domains on this important protein.
Although it
is not yet possible to determine the dissociation constant for
cryptophycin binding to tubulin, cryptophycin, and rhizoxin
demonstrated similar potencies for reducing the binding of
[H]vinblastine to tubulin (Fig. 8A). Since direct binding studies with
[
H]rhizoxin have suggested a k
of approximately 0.2 µM and a stoichiometry of 1 for
that drug(57) , it is likely that the affinity of cryptophycin
for this site is similar. We are currently synthesizing
H-labeled cryptophycin to directly determine the kinetic
constants and stoichiometry of its association with tubulin. It is
notable that cryptophycin is significantly more potent than vinblastine
and rhizoxin with regard to its antimicrotubule effects in intact
cells. For example, treatment of cells with only 25 nM cryptophycin blocked paracrystal formation in response to 5
µM vinblastine, while 5 µM rhizoxin was
required for similar competition with vinblastine (Fig. 9). The
roles of differences in rate constants for drug binding to and
dissociation from tubulin and/or differential intracellular
accumulation of the drugs are not yet known.
The apparent irreversibility of the effects of cryptophycin on microtubules both in intact cells and in vitro may prove useful for structural studies. Because of the propensity of high concentrations of tubulin to form amorphous aggregates, the three-dimensional structure of this protein has remained unsolved by either crystallographic or NMR technologies. Complexes of cryptophycin and tubulin may form crystals suitable for x-ray analysis.
In summary, the newly described antimitotic agent cryptophycin is able to interact with the Vinca alkaloid-binding site of tubulin with high potency and efficacy. This interaction causes markedly substoichiometric and virtually irreversible inhibition of microtubule polymerization. Therefore, while the overall effects of cryptophycin are similar to those of other antimitotic drugs, the molecular details of its interaction with tubulin are unique.